Filtered By:
Condition: Heart Failure
Nutrition: Calcium

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 213 results found since Jan 2013.

Inotropic and lusitropic effects of calcitonin gene-related peptide in the heart
Previous studies have demonstrated positive-inotropic effects of calcitonin gene-related peptide (CGRP), but the mechanisms remain unclear. Therefore, two experiments were performed to determine the physiological correlates of the positive-inotropic effects of CGRP. Treatments designed to antagonize the effects of physiologically active CGRP1–37 included posttreatment with CGRP8–37 and pretreatment with LY-294002 (LY, an inhibitor of phosphatidylinositol 3-kinase), 17β-estradiol (E), and progesterone (P) were also used to modulate the effects of CGRP1–37. Experiment 1 was in vitro studies on sarcomer...
Source: AJP: Heart and Circulatory Physiology - June 1, 2013 Category: Cardiology Authors: Al-Rubaiee, M., Gangula, P. R., Millis, R. M., Walker, R. K., Umoh, N. A., Cousins, V. M., Jeffress, M. A., Haddad, G. E. Tags: CARDIOVASCULAR NEUROHORMONAL REGULATION Source Type: research

Coffee and tea: perks for health and longevity?
Abstract PURPOSE OF REVIEW: Tea and coffee, after water, are the most commonly consumed beverages in the world and are the top sources of caffeine and antioxidant polyphenols in the American diet. The purpose of this review is to assess the health effects of chronic tea and/or coffee consumption. RECENT FINDINGS: Tea consumption, especially green tea, is associated with significantly reduced risks for stroke, diabetes and depression, and improved levels of glucose, cholesterol, abdominal obesity and blood pressure. Habitual coffee consumption in large epidemiological studies is associated with reduced mortali...
Source: Diabetes Metab - September 25, 2013 Category: Endocrinology Authors: Bhatti SK, O'Keefe JH, Lavie CJ Tags: Curr Opin Clin Nutr Metab Care Source Type: research

Understanding Digoxin
 Most of us have heard of, or encountered a patient taking Digoxin at some point in our carreers. But, do we understand what it is and how it affects our patient?    Digoxin (Lanoxin), is a Cardiac Glycoside, derived from the foxglove plant, Digitalis. This medication is often seen in the pre-hospital setting, used for the treatment of:    Heart Failure (HF) with reduced Systolic Function   Atrial Fibrillation (AF) and Atrial Flutter (A-flutter) associated with Rapid Ventricular Response (RVR)   Cardiomyopathies   Often combined with Calcium and Beta Channel Blockers, Angiot...
Source: EMS 12-Lead - January 10, 2014 Category: Cardiology Authors: Ivan Rios Tags: Atrial Fibrillation Bidirectional Ventricular Tachycardia Digoxin Digoxin toxicity Heart Failure Source Type: research

Elevated Parathyroid Hormone, But Not Vitamin D Deficiency, Is Associated With Increased Risk of Heart Failure in Older Men With and Without Cardiovascular Disease Original Articles
Conclusions— Elevated PTH, but not 25-hydroxyvitamin D or other markers of mineral metabolism, is associated with increased risk of HF in both older men with and without myocardial infarction/stroke. This increased risk was not explained by its association with known risk factors for HF. Further studies are now needed to elucidate the mechanisms underlying this association.
Source: Circulation: Heart Failure - September 16, 2014 Category: Cardiology Authors: Wannamethee, S. G., Welsh, P., Papacosta, O., Lennon, L., Whincup, P. H., Sattar, N. Tags: Congestive, Epidemiology Original Articles Source Type: research

Racial Differences in Incidence and Clinical Course of Atrial Fibrillation and What Remains to be Investigated
Abstract There are many risk factors identified for atrial fibrillation (AF), some of which differ between blacks and whites. These differences and differences in stroke occurrence and clinical course of AF between blacks and whites are reviewed. Risk factors identified to date include age, white race, male sex, body mass index (BMI) ≥30, height ≥173 cm, weight, increased waist circumference, higher levels of systolic (SBP) and diastolic blood pressure (DBP), increased pulse pressure, diagnosis of hypertension, antihypertensive medication use, HDL <40 mg/dL, triglycerides >200 mg/dL, lower heart rate...
Source: Current Cardiovascular Risk Reports - January 27, 2015 Category: Cardiology Source Type: research

Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis.
CONCLUSION: Cardioversion appears as a safe procedure with a reasonably acceptable cardiovascular event rate. However, to prevent the cardiovascular events, several risk factors should be considered before cardioversion. PMID: 26446636 [PubMed - in process]
Source: Yonsei Medical Journal - October 9, 2015 Category: Universities & Medical Training Authors: Shin DG, Cho I, Hartaigh BÓ, Mun HS, Lee HY, Hwang ES, Park JK, Uhm JS, Pak HN, Lee MH, Joung B Tags: Yonsei Med J Source Type: research

Management of Atrial Fibrillation
Atrial fibrillation remains the most prevalent cardiac arrhythmia, and its incidence is increasing as the population ages. Common conditions associated with an increased incidence include advanced age, hypertension, heart failure, and valvular heart disease. Patients with atrial fibrillation may complain of palpitations, fatigue, and decreased exercise tolerance or may be completely asymptomatic. Options for treating patients who experience atrial fibrillation include rate-controlling drugs such as digoxin, β-blockers, and calcium channel blockers or a rhythm-controlling strategy with agents such as sodium channel blo...
Source: Journal of Intensive Care Medicine - October 29, 2015 Category: Intensive Care Authors: Zamani, P., Verdino, R. J. Tags: Analytic Reviews Source Type: research

Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure – meta-analyses of randomized trials
Conclusion: BP-lowering treatment effectively prevents ’new onset’ heart failure. It is suggested that BP lowering by calcium antagonists is effective as BP lowering by other drugs in preventing ‘new-onset’ heart failure, unless the trial design creates an unbalance against calcium antagonists.
Source: Journal of Hypertension - January 30, 2016 Category: Cardiology Tags: Reviews Source Type: research

Preeclampsia and the Risk of Future Vascular Disease and Mortality: A Review
DiscussionPreeclampsia is associated with an increased risk for future chronic hypertension, CVD, cerebrovascular disease, and death. While evidence shows that women with cardiac risk factors may have a higher chance of developing preeclampsia, many women with preeclampsia have no CVD risk factors. Measures to prevent preeclampsia such as calcium supplementation for women with low calcium intake and low‐dose aspirin for women with a history of more than one incident of preeclampsia or a preterm birth associated with preeclampsia are supported by evidence. Reduction of modifiable risks associated with CVD before, during, ...
Source: Journal of Midwifery and Women's Health - February 29, 2016 Category: Midwifery Authors: Mayri Sagady Leslie, Linda A. Briggs Tags: Review Source Type: research

Beta-blockers for hypertension.
CONCLUSIONS: Most outcome RCTs on beta-blockers as initial therapy for hypertension have high risk of bias. Atenolol was the beta-blocker most used. Current evidence suggests that initiating treatment of hypertension with beta-blockers leads to modest CVD reductions and little or no effects on mortality. These beta-blocker effects are inferior to those of other antihypertensive drugs. Further research should be of high quality and should explore whether there are differences between different subtypes of beta-blockers or whether beta-blockers have differential effects on younger and older people. PMID: 28107561 [PubMe...
Source: Cochrane Database of Systematic Reviews - January 19, 2017 Category: Journals (General) Authors: Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH Tags: Cochrane Database Syst Rev Source Type: research

Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: an overview of systematic reviews
Conclusion: The available evidence supports treatment in people with type 2 diabetes and SBP more than 140 mmHg, using any of the major antihypertensive drug classes.
Source: Journal of Hypertension - January 31, 2017 Category: Cardiology Tags: Reviews Source Type: research

A Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts.
Conclusions -Among adults without known CVD, a novel multimodality testing strategy using ECG-LVH, CAC, NT-proBNP, hs-cTnT and hs-CRP significantly improved global CVD and ASCVD risk assessment. PMID: 28360032 [PubMed - as supplied by publisher]
Source: Circulation - March 30, 2017 Category: Cardiology Authors: de Lemos JA, Ayers CR, Levine BD, deFilippi CR, Wang TJ, Hundley WG, Berry JD, Seliger SL, McGuire DK, Ouyang P, Drazner MH, Budoff MJ, Greenland P, Ballantyne CM, Khera A Tags: Circulation Source Type: research

A Review of Mathematical Models for Muscular Dystrophy: A Systems Biology Approach
Discussion With new developments in computational power and data availability, a growing amount of research is using a systems biology approach to understand pathogenesis and progression of disease. Effective and integrated in vitro and in silico models could inform biological phenomena, even without the need of a living subject. For instance, over the last few decades, collagen hydrogel with muscle derived cells (CHMDCs) have promised to revolutionize in vitro experiments and tissue engineering. For CHMDCs to reach the envisioned use, verification by use of mathematical simulations are needed. Recently while examining sha...
Source: PLOS Currents Muscular Dystrophy - February 16, 2018 Category: Neurology Authors: Matthew Houston Source Type: research

Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis
Conclusions: Although only ACEIs have evidences showing its effect in reducing cardiovascular events and all secondary outcomes, head-to-head comparisons did not provide strong evidence in difference in the effects between these blood pressure-lowering drugs.
Source: Journal of Hypertension - May 1, 2018 Category: Cardiology Tags: Reviews Source Type: research